Stockwinners Market Radar for July 06, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:46 EDT Tesla exec sells $691K in common stock - In a regulatory filing, Tesla disclosed that its SVP of Automotive, Xiaotong Zhu, sold 2.6K shares of common stock on July 3rd in a total transaction size of $691K.

20:19 EDT Cathie Wood's ARK Investment bought 96.3K shares of Verve Therapeutics today

18:16 EDT Mercury Systems announces Bill Ballhaus assumes chairman role, board reduction - Mercury Systems announced a continuation of recent actions by the board of directors through board leadership changes and the appointment of an additional independent director. Bill Ballhaus, Mercury's interim president and CEO, will assume the role of chairman of the board, effective immediately prior to the annual meeting of shareholders. As previously announced, William O'Brien, the board's current chairman, will retire at that time. Mary Louise Krakauer has decided to retire from the board, effective immediately prior to the annual meeting and as a consequence, Howard Lance will assume the position of chair of the human capital and compensation committee at that time. Consistent with the board's ongoing commitment to refreshment, it has appointed Scott Ostfeld as a Class II director, effective immediately upon conclusion of customary onboarding. As a result of these changes, the board has approved a reduction by two seats to the board that will be effective immediately prior to the annual meeting. As of the annual meeting, the board will be comprised of nine directors, five of whom will have been appointed to the board in the past two years.

17:38 EDT Quanterix launches LucentAD biomarker blood test for AD patients - Quanterix "announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease, or AD. The LucentAD test, which will be available to healthcare providers as an aid in conjunction with other diagnostic tools, provides clinicians with a simplified process to quickly assess the likelihood of a patient having amyloid pathology consistent with AD. This information will help healthcare providers determine appropriate follow up and treatment planning for a suspected Alzheimer's patient."

17:35 EDT Mallinckrodt board actively evaluating capital needs amid opiod settlement - As previously disclosed, the Board of Directors of Mallinckrodt s engaged in discussions with various stakeholders, including parties holding substantial positions across the Company's capital structure and representatives of the Opioid Master Disbursement Trust II . The Board is actively evaluating the Company's capital needs in light of its obligations under its opioid settlement and its long-term debt, and is considering options, including transactions that have been proposed by holders of various series of the Company's indebtedness and other Company stakeholders, as well as the viewpoints of various parties in interest. As previously disclosed, in connection with these ongoing discussions, on June 15, the Company, certain subsidiaries of the Company and the Trust entered into Amendment to that certain Opioid Deferred Cash Payments Agreement, dated as of June 16, among the Parties which extended to June 23 from June 16, the date on which a $200M payment is required to be made to the Trust. As previously disclosed, (i) on June 22, 2023, pursuant to the Amendment, the Trust provided written notice that it was further extending the due date of the Opioid Deferred Cash Payment from June 23 to June 30 and (ii) on June 29 pursuant to the Amendment, the Trust provided written notice that it was further extending the due date of the Opioid Deferred Cash Payment from June 30 to July 7. ..The Company continues to analyze its situation and engage with various stakeholders, including representatives of the Trust. There can be no assurance of the outcome of this process, including whether or not the Company may make a filing in the near term or later under the U.S. Bankruptcy Code or analogous foreign bankruptcy or insolvency laws.

17:31 EDT Airbnb CEO sells $3.97M in common stock - In a regulatory filing, Airbnb disclosed that its CEO Brian Chesky sold 30K shares of common stock on July 3rd in a total transaction size of $3.97M.

17:25 EDT TH International opens 700th store and expands in China's Northwest - TH International has opened its 700th coffee shop and expanded into China's Northwest as part of its broader growth plans. The 700th store is the first in the northwest city of Yinchuan. The Yinchuan store is one of dozens of franchised stores that Tims China is opening in June and July, a key part of the company's strategy to expand its geographic reach to over 1,000 locations by the end of 2023.

17:18 EDT Lockheed Martin awarded $122.71M Navy contract modification - Lockheed Martin was awarded a $122.71M cost-plus-fixed-fee modification to a previously awarded contract. This modification definitizes critical technical refresh actions in support F-35 Joint Strike Fighter pilot and maintainer training site stand-up, schedules, support capability, and overall training system sustainment. Additionally, this modification adds scope to provide non-recurring engineering and necessary materials to refresh end of life components in fielded F-35 JSF pilot and maintainer training devices for the Air Force, Marine Corps, Navy, Foreign Military Sales customers, and non-U.S. Department of Defense participants. Naval Air Systems Command is the contracting activity.

17:10 EDT First Watch Restaurant director sells $7.39M in common stock - In a regulatory filing, First Watch Restaurant disclosed that its director Tricia Glynn sold 450K shares of common stock on July 3rd in a total transaction size of $7.39M.

17:09 EDT Birkenstock owner considers IPO at $6B or more value, Bloomberg reports - German sandal maker Birkenstock which is owned by an affiliate of LVMH (LVMUY) is getting ready to explore becoming a public company via an initial public offering, reports Bloomberg's Eyk Henning and Crystal Tse . "The iconic German sandal maker could be valued at more than $6B in an IPO, said one of the people, asking not to be identified because the details are private," added Bloomberg. Other public companies in the casual shoe and sneaker space include Allbirds (BIRD), Skechers (SKX) ,Nike (NKE) and Crocs (CROCS) Reference Link

17:01 EDT SS&C names Brian Schell as new CFO - SS&C "announced the appointment of Brian Schell as Executive Vice President and Chief Financial Officer. He will report to Bill Stone, Chairman and Chief Executive Officer. Mr. Schell will join SS&C on August 7 from Cboe Global Markets, where he was Executive Vice President, CFO, and Treasurer. He has more than 30 years of experience at global financial institutions, including H&R Block, the FDIC, KPMG and JP Morgan. At Cboe, he managed several successful acquisitions and subsequent integrations, such as Bats Global Markets, as well as the acquisitions of EuroCCP and BIDS Trading."

16:47 EDT Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi - The Food and Drug Administration converted Biogen (BIIB) and Eisai's (ESALY) Leqembi, indicated to treat adult patients with Alzheimer's Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit. Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer's disease, the agency said in a statement. The drug works by reducing amyloid plaques that form in the brain, a defining pathophysiological feature of the disease, it added. Leqembi was approved in January under the accelerated approval pathway. Reference Link

16:45 EDT FDA converts Biogen Alzheimer's treatment to full approval

16:36 EDT Costco reports total June comparable sales down 1.4% - Costco reported net sales of $22.86B for the retail month of June, the five weeks ended July 2, an increase of 0.4% from $22.78B last year. For the forty-four weeks ended July 2, the company reported net sales of $196.93B, an increase of 4.6% from $188.34B during the similar period last year. Total company comparable sales for June fell 1.4%. However, total company comparable sales for June, excluding the impacts from changes in gasoline prices and foreign exchange, rose 3%.

16:32 EDT Constellation Brands announces retirement of Rob Sands as board Chair - Constellation Brands "announced that Rob Sands will retire from his role as Chair of Constellation's Board of Directors and will not stand for re-election as Board Chair following the company's Annual Meeting of Stockholders on July 18, 2023. Sands will continue in his capacity as a Board member for the company. Constellation's Board has engaged in a process to identify a new Board Chair and will provide an update following the company's Annual Meeting of Stockholders on July 18, 2023."

16:30 EDT Costco reports total June SSS down 1.4% - Costco Wholesale Corporation reported net sales of $22.86B for the retail month of June, the five weeks ended July 2, an increase of 0.4% from $22.78B last year. For the forty-four weeks ended July 2 the Company reported net sales of $196.93B, an increase of 4.6% from $188.34B during the similar period last year.

16:22 EDT Biogen trading halted, news pending

16:18 EDT Akanda discloses Nasdaq listing deficiency notice - International medical cannabis platform company Akanda "announced that the Company has received a written notification on July 3, 2023 from the Listing Qualifications Department of the Nasdaq Stock Market LLC, notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value, was below $1.00 per share for a period of 30 consecutive business days."

16:13 EDT Levi Strauss falls 5% to $13.58 after Q2 results, guidance cut

16:10 EDT SPS Commerce names Chad Collins a new CEO, effective October 2 - SPS Commerce announced the appointment of Chad Collins as its new Chief Executive Officer, effective October 2. Mr. Collins will succeed current CEO Archie Black, who will retire from his position effective October 1 , and will transition to the newly created role of Executive Chair of the Board, as part of the previously announced succession plan.

16:09 EDT Camping World wins over $7M in verdict - Camping World won a total victory over sweeping claims of fraud and misconduct arising from the unscripted television series on CNBC, The Profit. The publicly-filed complaint sought in excess of $30M and punitive damages. The claims were brought by Gerard Fox Law on behalf of the estate of Precise Graphix, a participant on multiple episodes of The Profit. In her opinion, the Arbitrator found a "complete failure of competent, credible evidence" supporting Precise Graphix's allegations and that "Marcus Lemonis, at all times, acted in good faith with regard to Precise Graphix . . ." Judge Jones reject every one of the claims, and also awarded over $7M to the defendants. First raised in May 2022, the case was transferred by a Los Angeles Superior Court judge to Judicial Arbitration and Mediation Services in Los Angeles shortly thereafter under the parties' agreement.

16:01 EDT McGrath RentCorp acquires container rental company in Colorado - McGrath RentCorp "announced it has acquired the assets of Inland Leasing and Storage, a regional provider of portable storage solutions in the Colorado market. The transaction was funded with borrowings from McGrath's revolving credit facility. The acquisition adds approximately 600 assets to McGrath's portable storage operations in Colorado."

15:02 EDT Cronos Group up 4% after Reuters report on acquisition interest

14:41 EDT Worldwide ChatGPT traffic dropped 9.7% from May to June, Similarweb says - Israeli based software & data company specializing in web analytics, Similarweb, blogged in part, earlier: "ChatGPT no longer looks like it will keep growing until it's the most-trafficked website in the world. In other words, Google (GOOG,GOOGL)is in no danger of being eclipsed by the OpenAI tech demo site that turned into a cultural phenomenon. We reported last month that ChatGPT's skyrocketing traffic growth was beginning to level out, but this is the first month it's actually declined...Worldwide desktop and mobile web traffic to the ChatGPT website, chat.openai.com, dropped 9.7% from May to June, according to preliminary estimates. In the U.S., the month-over-month decline was 10.3%." Other competitors of ChatGPT are considered to include publicly listed Microsoft (MSFT), Amazon (AMZN). Reference Link

14:36 EDT Amylyx says Government of Quebec to cover ALBRIOZA for ALS - Amylyx Pharmaceuticals Canada announced that the company has entered into a Product Listing Agreement with Quebec for the public reimbursement of ALBRIOZA, effective July 6, 2023. The treatment will be included on the List of Medications reimbursed under Regie de l'assurance maladie du Quebec, or RAMQ, for the treatment of amyotrophic lateral sclerosis, or ALS, often known as Lou Gehrig's disease or maladie de Charcot. In the CENTAUR clinical trial, ALBRIOZA was shown to significantly slow disease progression and loss of functional decline in people living with ALS, potentially giving them more time with functional independence. Amylyx is currently working with other provincial, territorial and federal drug plans to have ALBRIOZA listed on public formularies across the country.

14:26 EDT Music streaming service 'TikTok Music' launches in Brazil and Indonesia - TikTok parent ByteDance said in part earlier, on its Brazil blog site: "ByteDance announces the launch of TikTok Music, a subscription-only music streaming service, in Brazil and Indonesia. This new social music streaming service will leverage TikTok's music discovery process, which is already famous for boosting artists and creating hits, helping users to enjoy their favorite viral songs, offering the ability to listen, download and share the tracks with their communities, as well as a smooth transition from TikTok to TikTok Music." Publicly traded companies that may be impacted by this news include Spotify (SPOT) and Apple (AAPL). Reference Link

14:01 EDT Revenue recognition from China could be pushed out to year-end, Mahdi says

14:00 EDT Clean Energy Technologies CEO 'optimistic about continued growth ahead'

13:31 EDT iRobot falls 1% after EU opens in-depth review of Amazon buyout

12:00 EDT Li-Cycle falls -10.1% - Li-Cycle is down -10.1%, or -59c to $5.29.

12:00 EDT Joby Aviation falls -11.0% - Joby Aviation is down -11.0%, or -$1.18 to $9.51.

12:00 EDT Sweetgreen rises 13.4% - Sweetgreen is up 13.4%, or $1.75 to $14.79.

11:34 EDT Stellantis, NioCorp sign rare earth offtake term sheet - Stellantis (STLA) and NioCorp Developments (NB) announced the signing of a rare earth offtake term sheet whose objective is to enter into a definitive rare earth supply agreement to support Stellantis' commitment to build resilient supply chains and reach carbon net zero by 2038 and to help accelerate NioCorp's path to commercial production of magnetic rare earth oxides in the U.S. "The Term Sheet executed today envisions a definitive agreement for a 10-year offtake contract for specific amounts of neodymium-praseodymium oxide, dysprosium oxide, and terbium oxide that NioCorp aims to produce at its Elk Creek Critical Minerals Project in southeast Nebraska, subject to the receipt of adequate project financing. Final volumes would be set in a definitive agreement.. As no economic analysis has been completed on the rare earth mineral resource comprising the Elk Creek Project, further studies are required before determining whether extraction of rare earth elements can be reasonably justified and is economically viable after taking account of all relevant factors. The entrance into a binding off-take agreement is subject to the satisfactory completion of due diligence, the negotiation and settlement of final terms, the negotiation of definitive documentation, and customary closing conditions, including regulatory approvals. There can be no assurance that any binding agreement will be entered into on the terms described herein or at all," the companies stated.

10:50 EDT Bear Cave joins Wolfpack Research, sees 'problems' at Applied Digital - In a recently published report, Edwin Dorsey writes that "The Bear Cave believes Applied Digital relies on puffery over substance and is a perfect case study on our market's bizarre underbelly of reverse mergers, microcaps, and shell companies." Saying it sees "problems" at Applied Digital, Bear Cave also notes that the shares are now up over 800% in the last twelve months as the company changed its name to focus on "next generation datacenters," which made "a community of retail investors excited about the company's ambition to 'lead the datacenter evolution.'" Earlier this morning, Wolfpack Research also issued a short report on the name. Reference Link

10:44 EDT EdtechX Holdings Acquisition Corp II trading resumes

10:32 EDT Estee Lauder shares clinical findings at World Congress of Dermatology - The Estee Lauder Companies announced that the company and several of its brands presented a range of novel preclinical and clinical findings at the 25th World Congress of Dermatology, held this week in Singapore. Poster details highlighting key data include: The benefits of regular use of moisturizer to skin aging prevention: a six-month evaluator blinded, randomized, and controlled clinical study, with results revealing that regular application of a potent moisturizer can not only treat skin dryness, but also improve the dry skin stratum corneum cohesion to reduce the appearance of facial aging; The effect of a multi-ingredient facial cream on skin structure, function, and appearance, with findings suggesting the facial cream provides an effective treatment for improving barrier integrity and strength as well as signs of aging parameters and skin appearance with regular daily use.

10:22 EDT Eco Wave Power's share repurchase program approved by shareholders - Eco Wave Power Global announced that its intention to set up a share repurchase program to repurchase American Depositary Shares corresponding to up to 10% of the total number of shares in the Company, which is the maximum amount permitted by the Swedish Law, was approved by Eco Wave Power's shareholders at the 2023 Annual General Meeting. The authorization for the repurchase is conditional on necessary permits being obtained from the Swedish Financial Supervisory Authority.

10:17 EDT Applied Digital drops 16% to $7.55 after Wolfpack short report

10:10 EDT Geospace announces resignation of CTO Michael Sheen - In a regulatory filing, Geospace said that on June 29, Michael J. Sheen notified the company of his intention to retire and resign from his position as Senior Vice President and Chief Technical Officer of the company, to be effective June 30, 2023. In connection with his retirement, Sheen and the company have entered into an employment termination and consulting agreement. Under the terms of the Consulting Agreement, Sheen will provide consulting services to the company at its request from time to time beginning July 1, 2023 for a period of one year, renewing automatically for subsequent one-year terms thereafter, unless either party provides written notice of its intent to terminate the Consulting Agreement at least 30 days prior to the expiration of the then current Term, Geospace said.

10:02 EDT Marsh McLennan Agency acquires Integrity HR, terms not disclosed - Marsh McLennan Agency announced the acquisition of Integrity HR, Inc., a human resources consulting firm based in Louisville, Kentucky. Terms of the acquisition were not disclosed. Founded in 2007, Integrity HR serves midsize clients across industries and sectors, including non-profits, private equity portfolio firms, family-owned businesses, governments, and municipalities, with strategic outsourced human resources and HR consulting services. Integrity HR will become part of Marsh McLennan Agency's national Employee Health & Benefits division, expanding its offerings to include a full suite of new HR capabilities, including compensation consulting, executive succession planning, and talent acquisition. Integrity HR's 13 employees, including Amy Newbanks Letke, Founder & CEO, will join Marsh McLennan Agency and continue to work out of their Louisville office.

10:00 EDT Bank United Corporation falls -7.6% - Bank United Corporation is down -7.6%, or -$1.21 to $14.78.

10:00 EDT Holley rises 8.4% - Holley is up 8.4%, or 32c to $4.11.

10:00 EDT Genius Sports rises 13.3% - Genius Sports is up 13.3%, or 77c to $6.58.

09:50 EDT Modine acquires Napps Technology, terms not disclosed - Modine announced that it acquired Napps Technology. This acquisition is in line with Modine's growth strategy to provide differentiated technologies and systems that help customers address real-world concerns, such as improving indoor air quality in schools. Modine currently serves the approximately $2 billion North American chiller market with large chillers targeting the data center market. The acquisition of Napps Technology allows Modine to enhance its offerings to the K-12 school market, while also enabling Modine to serve a broader range of customers and end markets seeking small tonnage chillers and chillers with heat pumps. Modine expects to generate between $6 million to $8 million in revenue this year from the acquisition and forecasts doubling that within two years. Modine also announced that it will continue to manufacture in Longview, Texas, and that Sam Neale, current president of Napps Technology, will join Modine.

09:48 EDT Gilead raises stake in Arcus Biosciences to 35% - Gilead Scienes disclosed an increased stake in Arcus Biosciences of 35%, which represents over 25.58M shares. On June 27, Gilead entered into an amended purchase agreement pursuant to which Gilead agreed to purchase an additional 1.01M shares of Arcus common stock at a purchase price of $19.26 per share. The purchase occurred on June 28. Under the amended purchase agreement, Gilead also has the right, at its option, to purchase additional shares from Arcus, up to a maximum of 35% of the company's then-outstanding common sock, from time to time for a period of five years from the closing of the initial purchase, at a purchase price equal to the greater of a 20% premium to market at the time Gilead exercises such option.

09:47 EDT Talos Energy falls -5.2% - Talos Energy is down -5.2%, or -72c to $13.19.

09:47 EDT Debt Resolve rises 5.3% - Debt Resolve is up 5.3%, or $2.31 to $45.96.

09:47 EDT Genius Sports rises 12.7% - Genius Sports is up 12.7%, or 74c to $6.55.

09:39 EDT Volkswagen launches first autonomous driving test program in the U.S. - Volkswagen Group of America (VWAGY) is starting its first autonomous vehicle test program in Austin beginning in July 2023. The company will kick off its program with a batch of 10 all-electric ID. Buzz vehicles outfitted with an autonomous driving technology platform developed by the global Volkswagen Group in partnership with technology company Mobileye (MBLY). Over the next three years, VWGoA plans to grow its test fleet in Austin and also progressively expand testing operations to at least four more American cities. Building upon investments throughout this initial pilot, VWGoA anticipates a commercial launch of autonomous driving vehicles in Austin by 2026. The start of VWGoA's test program in the U.S. marks a further push for Volkswagen Group's global autonomous driving vehicle research and development, the company says. VWGoA will lead the strategy and business development in the U.S., and has established a subsidiary named Volkswagen ADMT, LLC1 to support the rollout of its autonomous driving vehicle program, with teams in Belmont, Calif. and Austin, Texas. The company plans to also employ team members who worked with Argo AI.

09:37 EDT Infosys opens subsidiary Infosys Public Services Canada - Infosys Public Services announced the opening of its new subsidiary, Infosys Public Services Canada, headquartered in Ottawa, Ontario with local offices in Mississauga ON, Calgary AB, and Burnaby BC. IPS Canada accelerates digital transformation for public sector organizations across the country, including federal departments, provincial ministries, municipalities, and crown corporations, and provides access to top tier IT talent and innovative solutions to improve the delivery of government services to Canadians. Infosys Public Services' Canadian expansion marks the next phase of its decade-plus presence in the country and is the logical next step for the company given its growth in Canada and the evolving government security standards and regulation. This IPS Canada announcement is the latest development in a series of investments made by Infosys which has expanded the employee count to over 7,000 with a commitment to increase to 8,000 employees by 2024. IPS Canada will also work with local universities and technical colleges to recruit talent.

09:32 EDT Marriott Vacations appoints Raman Bukkapatnam as CIO - Marriott Vacations Worldwide (VAC) announced that Raman Bukkapatnam will join the Company as Chief Information Officer, effective July 10, 2023. As a member of the Company's Executive Committee, Bukkapatnam will report directly to John Geller, President and CEO. In his role, Bukkapatnam will be responsible for leading the enterprise's global technology strategy, transformation, and modernization. Prior to joining the Company, he served as Vice President, Global Technology at Nike (NKE).

09:28 EDT Terran Orbital Corp trading halted, news pending

09:21 EDT Cosmos Health completes acquisition of Cana Laboratories - Cosmos Health announced the closing of the acquisition of Pharmaceutical Laboratories CANA, a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies. The purchase price for acquiring all of the outstanding shares of Cana was approximately $1.67 million, consisting of EUR 800,000 in cash and $800,000 in stock, based on an issuance price of $17.25 per share. The acquisition price is considered to be significantly discounted to the current Fair Market Value of Cana's intangible and tangible assets, which are currently valued in excess of $10 million, based on independent valuation reports and market comparables. Consequently, Cosmos Health anticipates recording a substantial gain on bargain purchase, when considering the equity investment of $1.67 million in comparison to the FMV of assets exceeding $10 million.

09:19 EDT Jamf Holding announces integrations with Google Cloud - Jamf announced three new integrations with Google Cloud, enabling and protecting mobile workforces that use Google and Apple. Encompassing Zero Trust, observability, and identity workflows, Jamf continues to provide unique value for Google Cloud users with Apple devices. Jamf's integration with BeyondCorp now supports device compliance signals for iOS and iPadOS. The addition of Apple's mobile platforms builds on last year's release of the Jamf and Google Cloud's BeyondCorp integration for macOS. Jamf is the first management platform to support Apple desktop and mobile devices in this Zero Trust framework.

09:18 EDT Vislink appoints Steven Teese as VP, sales for the Americas - Vislink Technologies announced that Steven Teese has joined the company as Vice President of Sales for the Americas, effective immediately. Mr. Teese will lead Vislink's sales organization in the Americas, with a keen focus on accelerating the penetration of Vislink's market-leading video communications solutions in key public safety and live production markets. As National Sales Director for Watchguard Video, he led the growth from startup to $150 million in sales, resulting in an exit to Motorola Solutions.

09:16 EDT Atossa Therapeutics enters sponsored research agreement with Weill Cornell - Atossa Therapeutics announces a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor expression in triple-negative breast cancer. The goal of this research is to determine if treating TNBC with extracellular vesicles carrying the ER will convert the tumor to ER+ and render it sensitive to treatment with Selective Estrogen Receptor Modulators, including Atossa's proprietary (Z)-endoxifen. The research project will be led by David Lyden, M.D., Ph.D., the Stavros S. Niarchos Professor in Pediatric Cardiology and Director of the Department of Pediatrics' Physician Scientist Training Program at Weill Cornell Medicine. Dr. Lyden's laboratory is focused on the molecular pathways activated by tumor extracellular vesicle uptake at the metastatic site and identifying potential therapeutic targets to thwart metastasis. His work has led to a new understanding of how primary tumor cells dictate their own metastases, by decoding how cancer-derived extracellular vesicles mediate intercellular communication. Most recently, Dr. Lyden has identified specific extracellular vesicle subpopulations and discovered a new subset of particles known as exomeres, which collectively have distinct functional roles in the systemic effects of cancer.

09:13 EDT Starboard Value sends letter to Algonquin Power & Utilities - Starboard Value LP issued the below letter to Algonquin Power & Utilities Corp. regarding opportunities to enhance shareholder value. "Starboard Value recently filed a Schedule 13D disclosing an economic ownership stake of approximately 7.5% in Algonquin Power & Utilities Corp, making us the Company's largest shareholder... As we have discussed, we believe Algonquin's Regulated Services Group is a top tier regulated utility that is currently valued at a substantial implied discount to peers pro forma for a potential sale of all or a substantial majority of the Company's unregulated renewables assets... Algonquin's valuation has been hampered by a number of factors, most notably excessive leverage and a high dividend payout ratio. Algonquin's high payout ratio, its recent dividend cut, its high proportion of unregulated assets, and scars from the recently-abandoned Kentucky Power deal have all combined to make Algonquin uninvestible for a large portion of traditional utility investors. Fortunately, we believe these problems can be solved through a sale of all or a majority of the Renewable Energy Group. Pro forma for such a sale, we believe Algonquin would have lower leverage, a safer dividend, a greener asset base, and higher rate base growth than peers, and should be afforded a higher valuation... In particular, we believe your key objectives should be: Reduce leverage to industry-standard levels of approximately 5x gross leverage4. Once target leverage levels have been achieved, excess proceeds should be used to repurchase shares of Algonquin to drive EPS accretion. Improve EPS as much as possible, so that the dividend payout ratio is in-line with peers, with room for increases. As we have discussed, we believe a target of 75 cents in FY 2025 EPS5 is achievable."

09:10 EDT Borqs Technologies, SkyCentrics start commercial shipment of CTA-2045 devices - Borqs Technologies, together with SkyCentrics, have launched the next generation CTA-2045 ECOPORT communication products. Borqs and SkyCentrics announced their strategic partnership in 2021. The partnership includes joint research & development, sales, and promotion, as well as, Borqs' investment into SkyCentrics. SkyCentrics will be responsible for the CTA-2045 software, ECOPORT certification, and cloud functionality with its Demand Response Energy & Asset Management platform. The first release of the next generation ECOPORT will start commercial shipment in Q3, and both companies forecast strong demand for the products. SkyCentrics is working with major commercial building industrial equipment manufacturers to provide them retrofit kits that will enable their embedded base of existing equipment to be retrofit to have a CTA-2045 EcoPort.

09:09 EDT American States Water announces final decisions by CPUC in rate case - American States Water announced that the California Public Utilities Commission, or CPUC, adopted final decisions in connection with the general rate case and cost of capital proceedings at AWR's regulated water utility subsidiary, Golden State Water Company, or GSWC. The final decision in GSWC's general rate case proceeding will set new water rates for the years 2022 - 2024. The assigned administrative law judge at the CPUC had issued a proposed decision on April 13 that adopted the full settlement agreement between GSWC and the Public Advocates Office at the CPUC with new rates retroactive to January 1, 2022, (ii) approved GSWC's request for balancing accounts for medical and general liability insurance, (iii) denied GSWC's request to consolidate two of its customer service areas, and (iv) allowed for additional increases in adopted revenues for 2023 and 2024 subject to an earnings test and inflationary index values at the time of filing for implementation of the new rates. The final decision issued on June 29 is consistent in all material respects with the proposed decision issued in April, except it included a change to substitute the adoption of balancing accounts for medical and general liability insurance with memorandum accounts. As a result of receiving the final decision, on June 30, 2023 GSWC filed for the implementation of new 2023 rate increases using inflationary index values as of May 31, 2023. The new rates for 2023 are expected to go into effect on July 31. Within 90 days after 2023 rates have been implemented, GSWC will also file for recovery of retroactive amounts accumulated through July 31 related to the new 2022 and 2023 rates. Also on June 29, the CPUC unanimously adopted the proposed decision issued on May 9, 2023 in the cost of capital proceeding. The final decision adopts for GSWC an 8.85% return on equity, a 5.10% cost of debt and a capital structure of 57% equity and 43% debt, resulting in a 7.24% authorized return on rate base for the calendar year 2022. Based on the final decision, all adjustments to rates are interpreted to be prospective and not retroactive. The decision also continues the Water Cost of Capital Mechanism, or WCCM, for the years 2023 and 2024. On June 30, GSWC filed an advice letter to trigger the WCCM for 2023, which will increase the 8.85% adopted return on equity in the decision to 9.36% for the remainder of 2023 and 2024. The company said, "We are in the process of reviewing all of the impacts resulting from the two final decisions. This will include reassessing the accounting estimates recorded through March 31, 2023 from both decisions, including management's estimates of the cost of capital proceeding that resulted in the recording of lower revenues beginning in 2022 that were estimated to be refunded to customers to reflect the lower cost of debt in this proceeding (from 6.6% to 5.1%). Any true-up adjustments resulting from changes in estimates and circumstances will be recorded in the 2023 second quarter results that will be reported in our second quarter earnings release and Form 10-Q that will be filed with the Securities and Exchange Commission."

09:08 EDT Jeffs' Brands to acquire 50.01% interest in B24Chat business - Jeffs' Brands has entered into a non-binding letter of intent to acquire a majority controlling interest of the B24Chat business, an AI marketing platform specializing in enterprise-level omnichannel and conversational automation management. This acquisition signifies Jeffs' Brands' strategic entry into the AI domain, complementing its existing suite of businesses. B24Chat, an AI-based customer service platform, offers an omnichannel and conversational automation management solution that helps companies streamline their customer interactions across various platforms. Pursuant to the LOI and subject to entry into a definitive agreement, the parties will establish a new company in which Jeffs' Brands will invest an aggregate amount of $1,000,000, of which $500,000 will be paid in cash and $500,000 will be paid in newly-issued ordinary shares of Jeffs' Brands, in consideration for 50.01% of NewCo's fully diluted share capital. The founder of B24Chat shall assign all of its rights, title and interest in the technology of the B24Chat business in consideration for 49.99% of NewCo's fully diluted share capital. The B24Chat platform offers companies the ability to build and operate their own branded, sales-focused websites or easy-to-use iOS & Android apps. By connecting to a company's website, customer relationship management and/or enterprise resource planning, B24Chat's smart bots can "read" and "look" through content, gathering information about products and services, as well as updating news about the company and the market. The bot even learns on its own, developing unique scenarios to prepare for conversations with clients.

09:07 EDT Tenable Holdings joins Cloud Security Alliance - Tenable has joined the Cloud Security Alliance as Executive Member. CSA is an organization dedicated to defining standards, certifications and best practices to help ensure a secure cloud computing environment. As an executive level member, Tenable will champion preventive security approaches, helping organizations understand and reduce cybersecurity risk across their entire attack surface-from the cloud, IT, OT, identity systems and beyond.

09:06 EDT Wearable Devices completes development of bidirectional plugin for Unity - Wearable Devices announced the completion of the development of its new bidirectional plugin for Unity, a game engine supporting desktop, mobile, console, virtual reality and augmented reality platforms, establishing a live communication channel between the Unity game engine and the Mudra Inspire neural input wristband . The innovative plugin integrates touchless interaction and control into Unity supported platforms, expanding software development opportunities and enabling commercial gaming companies and enterprises to create increasingly customized experiences for their users. Through integration with the Company's Mudra Inspire neural input wristband, new creative and immersive experiences that redefine the boundaries of user interaction can be introduced into desktop, mobile, console and VR platforms.

09:05 EDT Pfizer, Arvinas and Carrick Therapeutics collaborate for oncological combination - Carrick Therapeutics, an oncology-focused biopharmaceutical company, announced a clinical trial collaboration and supply agreement with Arvinas (ARVN) and Pfizer (PFE). This agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick's samuraciclib, an oral and first-in-class inhibitor of CDK7, and Arvinas' vepdegestrant, an investigational oral Protac estrogen receptor protein degrader being developed in collaboration with Pfizer, in patients who have received prior CDK4/6i, with ER+, HER2- metastatic breast cancer. Arvinas will be the regulatory sponsor of the study in the U.S. and Pfizer will be the acting sponsor for the study conducted in the U.S., as well as the regulatory and acting sponsor of the study outside of the U.S. The three parties will collaborate through a Joint Development Committee. It is anticipated that the Phase 1b/2 trial will be initiated in the second half of 2023. Vepdegestrant is an investigational, orally-bioavailable Protac protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 negative breast cancer.

09:05 EDT Lightspeed says restauranteurs use LightSpeed Restaurant to serve over 1B meals - Lightspeed Commerce marks a game-changing milestone: restaurateurs have leveraged Lightspeed Restaurant to serve over one billion meals worldwide and facilitate more than 300 million unique diner's unforgettable experiences in the last 12 months through this powerful restaurant solution. This extraordinary feat highlights the increase in Lightspeed Restaurant's transaction volume growth.

09:03 EDT Lifezone Metals completes business combination with GoGreen Investments - Lifezone Metals announces that on July 6, 2023, Lifezone Holdings Limited completed the previously announced business combination with GoGreen Investments Corporation (GOGN), formerly a blank check company listed on the New York Stock Exchange. Lifezone Metals' ordinary shares and warrants are expected to begin trading on the NYSE under the ticker symbols "LZM" and "LZMW", respectively, at the opening of trading today. The Business Combination was implemented through a newly created holding company, Lifezone Metals. Upon completion of the Business Combination, GoGreen merged into a wholly-owned subsidiary of Lifezone Metals, after which GoGreen ceased to exist and the shareholders of GoGreen received shares in Lifezone Metals, and LHL was acquired by Lifezone Metals, after which LHL became an operating wholly-owned subsidiary of Lifezone Metals and the shareholders of LHL received shares in Lifezone Metals. The Company received gross proceeds from the transaction of approximately $86.6 million, including approximately $70.2 million in aggregate from a private investment in public equity and the receipt of approximately $16.4 million of cash from GoGreen's trust account, net of redemptions. Keith Liddell, Chairman of Lifezone Metals, said: "Today is a momentous occasion in the corporate evolution of Lifezone Metals and one we are immensely proud of. For nearly 30 years, Lifezone Metals' CTO Dr. Mike Adams and I have been developing and improving our Hydromet Technology as a cleaner, lower cost, and more efficient alternative to smelting in the metals extraction process."

09:02 EDT Bit Digital produced 119.1 BTC in June, up 5% from May - Bit Digital announced its unaudited digital asset production and corporate updates for the month of June 2023. Corporate Highlights for June 2023; In June 2023, the Company produced 119.1 BTC, a 5% increase compared to the prior month. The increase in production was primarily driven by a higher average active hash rate and was partially offset by a decrease in transaction fees compared to the prior month. The Company's active hash rate was approximately 1.78 EH/s as of June 30, 2023. Treasury holdings of BTC and ETH were 485.0 and 11,738.9 with a fair market value of approximately $14.8 million and $22.7 million, respectively, on June 30, 2023. The BTC equivalent of our digital asset holdings as of June 30, 2023 was approximately 1,445.2, or approximately $44.0 million. As of June 30, 2023, Bit Digital had transferred 129 BTC to its strategic partner, Auros Global Limited, as collateral for yield optimization strategies connected to 430 BTC that Auros is conducting on behalf of Bit Digital. This allocation relates to the Company's broader objective to enhance its overall treasury management solutions. The Company had cash and cash equivalents of $18.5 million as of June 30, 2023.

08:59 EDT Intercontinental Exchange reports June average daily volume up 5% y/y - Intercontinental Exchange reported June 2023 trading volume and related revenue statistics. "ICE had a strong second quarter and first half as customers utilize our multi-currency platform of global benchmarks across commodities, energy and interest rates to manage their risk exposure," said Ben Jackson, President at ICE. "The growth this year of ICE's flagship oil, natural gas, and soft commodity derivative markets, particularly Brent and TTF, show the crucial role these contracts play in reflecting global fundamentals to meet our customers' hedging needs, underpinned by the strength and liquidity of our commercial customer base. Total ADV up 4% y/y in Q2.

08:56 EDT CCL Industries acquires Creaprint for $38.1M - CCL Industries has acquired privately held Creaprint, based in Alicante, Spain. Creaprint is a specialist in mould label producer with a manufacturing facility in Alicante, Spain, and a sales office in Miami, Florida, with 2022 sales of $17.0 million and adjusted EBITDA of $5.1 million. The debt and cash-free purchase consideration of $38.1 million includes $5.9 million invested in a new production facility where operations will relocate later this year. The business will now trade as CCL Label, Spain and become an integral part of the Food & Beverage unit in Europe. Coincidentally, the recently announced acquisition of Pouch Partners S.r.l., Italy, from Pouch Partners AG, Switzerland, also closed.

08:55 EDT Ivanhoe Electric, Ma'aden formally establish exploration JV - Ivanhoe Electric announced the closing of the transactions with Saudi Arabian Mining Company Ma'aden. Ma'aden has invested $127.1 million in new common stock of Ivanhoe Electric to become a 9.9% shareholder. Ivanhoe Electric will contribute $66 million of the Ma'aden proceeds into the new Saudi Arabian exploration joint venture company known as "Ma'aden Ivanhoe Electric Exploration and Development Limited Company" to fund exploration activities and the purchase of three new-generation Typhoon machines. The Joint Venture will deploy the disruptive power of Typhoon to explore ~48,500 km2 of underexplored lands in the Arabian Shield that Ma'aden has made exclusively available to the Joint Venture. One of Ivanhoe Electric's existing three proprietary Typhoon geophysical surveying systems is expected to arrive in Saudi Arabia in August. Surveying programs could commence as soon as September of this year. Once Typhoon arrives in country, our joint Technical Committee will begin the extraordinary task of surveying for geophysical anomalies, potentially indicative of sulfide mineral deposits containing copper, nickel, gold and silver, over ~48,500 km2 of underexplored Arabian Shield. The Technical Committee has been working ahead of closing in order to prioritize targets for initial Typhoon surveys so that survey work can commence as soon as possible. Ivanhoe Electric has issued 10,269,604 shares of common stock to Ma'aden, representing 9.9% of the common stock outstanding following the issuance of the new shares to Ma'aden. The new shares were issued at a purchase price of $12.38 per share for gross proceeds of $127.1 million. $66 million of the proceeds will be contributed by Ivanhoe Electric to the Joint Venture to fund its activities. The remaining $61.1 million, net of appliable fees and expenses, will be used by Ivanhoe Electric to advance its US mineral projects, for working capital and general corporate purposes. Ivanhoe Electric has granted Ma'aden a top-up right allowing Ma'aden to maintain its 9.9% ownership. Ma'aden has agreed to a five-year standstill limiting its shareholding to a maximum of 19.9%, subject to certain exceptions. The strategic investment by Ma'aden has been approved by the Toronto Stock Exchange in reliance upon the exemption described in Section 602.1 of the TSX Company Manual, which is available to certain "eligible interlisted issuers" that have less than 25% of their overall trading volume on Canadian marketplaces. Sofia Bianchi has been appointed as Ma'aden's nominee to Ivanhoe Electric's Board of Directors, bringing the Company's board size to nine members.

08:51 EDT Siyata Mobile secures $1.4M SD7 order - Siyata Mobile announced that it has secured its largest SD7 order ever in the Company's history from a single customer. The order is valued at approximately $1.4 million. The Company expects to deliver this new order in the second half of 2023.

08:47 EDT Syla Technologies authorizes Y200M ADS repurchase proram - SYLA Technologies announced that its Board of Directors has authorized a repurchase program pursuant to which it may repurchase up to Y200M of its American Depositary Shares, each ADS representing one one-hundredth of a common share of the Company.

08:46 EDT Orbit's Simulator Products Solutions reports June bookings in excess of $3M - Orbit International announced that bookings from its Simulator Product Solutions LLC subsidiary for the month of June 2023 were in excess of $3,000,000 and its second quarter bookings were approximately $4,500,000. Deliveries for the June 2023 orders are expected to commence in the third quarter of 2023 and are expected to continue through the second quarter of 2024. In addition, the Company also announced that bookings for its Power Group for the month of June were approximately $1,000,000. Deliveries for these orders have already commenced and are expected to continue through the first quarter of 2024.

08:44 EDT Ebix provides strategic update - Ebix provided a strategic update, detailing the paths it is pursuing to achieve the goal of being a debt-free company in 2023. The company announced is progressing with its plan to complete an initial public offering of its EbixCash subsidiary in India. EbixCash intends to announce a IPO listing date publicly as soon as it has the requisite approvals in place.Ebix is in advanced stages of a part-asset sale exercise, with multiple bidding parties, with potential proceeds from the asset sale, being sufficient to repay 100% of its bank debt. Ebix has received bids from a mix of strategic and financial bidders who have already completed substantial due diligence. The company has recently filed the EbixCash financial addendum document in line with the regulatory guidance from Indian regulators, stating its payment solutions revenues on a net basis.

08:43 EDT ABVC BioPharma CEO Uttam Patil decides to forgo salary - ABVC BioPharma announced the new CEO of ABVC has chosen to forgo a salary, instead opting for stock options as a pivotal component of his compensation package. ABVC's current pipeline includes a completed Phase II study for a product aimed at major depressive disorder and discussions with the FDA regarding moving forward with the Phase III study. We are also advancing on a Phase IIb study in Attention Deficit Hyperactivity Disorder, ongoing at the University of California at San Francisco and the additional five sites in Taiwan. ABVC plans to accomplish these two tasks by the end of 2023. An evaluation is underway regarding reinstating the Vitargus trials and proceeding with the pivotal trials worldwide. Furthermore, BLEX 404, an oncology product for treating Non-Small Cell Lung Cancer and other cancer types based on combination therapy, has passed the IND approvals from US FDA and is in review at the Taiwan FDA to kick-start the trials.

08:40 EDT Alarum to scale down operations in Consumer Internet Access business - A purchase pause by the largest customer of CyberKick, the Company's Consumer Internet Access business unit, which accounted for approximately 60% of the consumer internet access segment and approximately 18% of the Company's total revenue for the second quarter of 2023, along with the above-mentioned factors in this segment, supported the decision to focus on revenue that yield high return on investment and profitability. The Company will scale down operations in the Consumer Internet Access business, with material expenses and headcount reductions, in order to right-size accordingly. Alarum will focus on this segment only on its current paying customers which require minor costs to maintain and generate revenues from. These transition measures taken by management will not impact on these existing Consumer Internet Access customers, and the Company remains committed to providing uninterrupted service and support. Further to the Company's announcement of January 18, 2022, regarding the appointment of TerraZone as the Company's exclusive reseller of its legacy cybersecurity solutions, Alarum has now entered into a definitive agreement with TerraZone for the sale of its enterprise cybersecurity business. Alarum's consideration for this transaction is 7% of the fully diluted share capital of TerraZone.

08:39 EDT Hillstream BioPharma licenses technology for proprietary antibody conjugates - Hillstream BioPharma signed an exclusive agreement with Applied Biomedical Science Institute - ABSI - to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes. The goal is to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates. The HER2/HER3 binding ADC is targeted to have a high drug-to-antibody ratio which should increase the anti-tumoral efficacy with an enhanced bystander killing effect. Hillstream intends to combat drug resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer. The Applied Biomedical Science Institute has developed technology to target novel functional epitopes of the cancer targets HER2 and HER3. ABSI has granted Hillstream an exclusive license agreement, and Hillstream will have the opportunity to develop HER2 and HER3 antibodies, including multi-specific, ADC, and Quatramer-based therapeutics utilizing portions of these antibodies.

08:36 EDT NRSInsights says June same-store sales increased 7.7% - NRSInsights announced comparative same-store sales results for June 2023. As of June 30, 2023, the NRS retail network comprised approximately 25,200 terminals scanning purchases at independent retailers including bodegas, convenience stores, liquor stores, grocers, and tobacco and sundries sellers nationwide, predominantly serving urban consumers. Retail Same-Store Sales Highlights: Same-store sales increased 7.7% from a year earlier. Average sales per calendar day for June increased 1.5% compared to the preceding month. Same-store sales in the preceding month had increased 7.1% compared to the year-ago month. Average sales per calendar day in May increased 1.0% compared to the preceding month. For the three months ended June 30, 2023, same-store sales increased 6.2% compared to the three months ended June 30, 2022; The number of items sold during June 2023 increased 7.3% compared to June 2022 and the number of items sold per calendar day increased 1.0% compared to May 2023. The average number of transactions per store in June 2023 increased 4.3% compared to June 2022 and the average number of transactions per store increased 1.4% compared to May 2023. A dollar-weighted average of prices for the top 500 items purchased in June 2023 increased 2.9% year-over-year, a slight decrease from the 3.2% year-over-year increase recorded in May 2023.

08:35 EDT Data Storage awarded subscription-based cloud services contract - Data Storage has secured a large, subscription-based contract with a promotional products company through its Flagship Solution Group subsidiary. The company has been contracted to provide fully monitored and managed cloud solutions. The solutions provide cloud based disaster recovery and cloud based infrastructure allowing the client to move from legacy hardware to running its critical applications on the company's enterprise cloud.

08:33 EDT Silicom launches Edge AI product line, enters partnership with Hailo - Silicom announced the first in a new line of Edge AI products, the first fruit of a new partnership that it has formed with Hailo, a leading Artificial Intelligence chipmaker. The new product line integrates Hailo's AI-accelerators into Silicom's existing Edge platforms, thereby solving performance challenges for Edge AI use cases. "We are excited to bring this powerful new Edge AI solution, our first AI-focused product, to the market," commented Liron Eizenman, Silicom's CEO. "By integrating Hailo's groundbreaking chips into our products, we are making it cost-effective to move behavior analytics, human intrusion detection, facial recognition and vehicle analytics to the edge. This will help our customers unlock new use cases and provide new revenue streams and more value to their customers. In fact, we are already engaged in POCs and in discussions with customers on different use cases."

08:32 EDT Myriad Genetics announces $90M asset-based credit facility - Myriad Genetics has established a new $90 million asset-based credit facility with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, and the other lender parties thereto consisting of Wells Fargo Bank, N.A. and Bank of America, N.A. The ABL Facility includes an option to increase the maximum principal amount by up to $25 million for a total of $115 million. The ABL Facility replaces the Company's previous credit facility and matures on June 30, 2026. The ABL Facility is secured by substantially all of the assets of Myriad Genetics and its subsidiaries. Additional details on the ABL Facility, including the interest rate on loans under the ABL Facility, are included in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 6, 2023.

08:32 EDT Envestnet's Elevate receives third consecutive choir certification - Envestnet announces that its Envestnet Summit 2023 - Elevate - a preeminent annual industry conference - has received the Choir Certification for conferences meeting standards for diversity, equity, and inclusion among speakers as well as panel moderators and participants. "At Envestnet, we are very proud to support this work and believe that while change can start small, providing a platform for diverse voices at conferences is a meaningful way to improve their representation in our industry," said Bill Crager, Co-Founder and Chief Executive Officer of Envestnet. "Through Envestnet Elevate, we are working side-by-side with Choir to amplify the voices of women, people of color, and other groups who have traditionally been underrepresented in finance-and we hope more organizations will join us in this effort."

08:31 EDT TTEC Holdings announces new customer experience delivery center in Brazil - TTEC Holdings announced the opening of a new customer experience delivery center in Brazil. "We are thrilled to relocate our Brazilian team into this new location in Sao Paulo," said Chuck Koskovich, chief operating officer of TTEC Engage. "TTEC has hundreds of employees in Brazil who will enjoy an improved experience with easier access to transportation, shopping, restaurants, and services. We are proud of the outstanding culture we've built in Brazil over the past 25 years that inspires associates to think big, innovate, grow, and relentlessly drive the company's values." This new delivery center hosts more than 430 seats across four floors.

08:30 EDT Stryker launches Ortho Q Guidance system - Stryker announced the launch of its Ortho Q Guidance system, the only fully autonomous system in the industry, easily controlled by the surgeon from the sterile field. "Ortho Q was designed specifically for our orthopaedic customers and is the culmination of a multiyear collaboration between teams in India, Germany and the United States. This platform builds a foundation for the future of orthopaedic surgical capability," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business.

08:29 EDT NextSource Materials completes 2.6MW solar farm at Molo Graphite - NextSource Materials announced that construction of the solar farm for the solar hybrid power plant at the Company's Molo Graphite mine in Madagascar has been completed. The Solar Hybrid Plant is owned and operated by CrossBoundary Energy under a 20-year power purchase agreement and consists of the 2.6 MW solar farm, a 3.1 MW thermal facility, and a 1 MWh battery energy storage system, which is expected to arrive in the next few weeks. The solar farm was constructed by CBE using local labour and comprises a total of 4,902 photovoltaic panels, covering 12,663 square metres, installed on ballasted mounting systems. The 2.6 MW solar farm is expected to produce approximately 4 GWh of clean energy per year, reducing the mine's all-in sustaining costs, and is expected to reduce carbon emissions by 2,275 tonnes annually. Final electrical interconnections between the solar farm with the mine are now underway and are expected to be completed within the coming weeks. The Solar Hybrid Plant is designed to generate 33% of the Molo mine's steady-state power requirements from renewable energy. The solar facility together with load balancing provided by the BESS will be capable of supplying up to 100% of the plant's power requirements during peak daylight hours, with the thermal facility supplying all off peak power requirements, thereby ensuring an uninterrupted power supply to the mine.

08:24 EDT Biodexa Pharmaceuticals announces publication on PNOC015 study - Biodexa Pharmaceuticals announced the publication of the results of an investigator-initiated Phase I study PNOC015 of MTX110 in the treatment of pediatric patients with DMG in the Journal of Neuro-Oncology. The study recruited seven pediatric patients with confirmed diagnosis of DMG, after radiation therapy. Convection Enhanced Delivery of MTX110 at doses escalating from 30microM to 90muM was performed, with a total of 48 infusions across all patients. The study has demonstrated acceptable safety profile of the treatment and encouraging efficacy with median overall survival of 26.1 months comparing favourably with historical data of OS of 10.0 months.

08:21 EDT Celldex doses first patient in Phase 2 study of barzolvolimab - Celldex Therapeutics announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in eosinophilic esophagitis. EoE is the most common type of eosinophilic gastrointestinal disease, a chronic inflammatory disease of the esophagus. Several studies have suggested that mast cells may be an important driver in this disease. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. The randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE. Approximately 60 patients will be randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment phase. Patients then enter a 12-week active treatment phase, in which all patients will receive barzolvolimab 300 mg every 8 weeks. Patients then enter a follow-up phase for an additional 16 weeks. The primary endpoint of the study is reducing esophageal intraepithelial infiltration of mast cells as assessed by peak esophageal intraepithelial mast cell count. Secondary endpoints include the reduction of symptoms of dysphagia and esophageal intraepithelial infiltration of eosinophils and safety. When all clinical trial sites are open, the study will include approximately 60 clinical trial centers across 8 countries, including the United States.

08:18 EDT Caribou Biosciences announces $25M investment from Pfizer - Caribou Biosciences (CRBU) announced that Pfizer (PFE) has made a $25 million equity investment in the company. Pfizer purchased 4,690,431 of Caribou common shares at a price of $5.33 per share, pursuant to the terms of a Securities Purchase Agreement dated June 29, 2023. The purchase by Pfizer closed on June 30, 2023. In conjunction with the investment, Sriram Krishnaswami, PhD, has joined Caribou's Scientific Advisory Board. Caribou will use the proceeds of this investment to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma. Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

08:15 EDT Vaxart reports positive topline Phase 2 data of norovirus vaccine candidate - Vaxart announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. Preliminary results of the trial showed robust serum immune responses across all doses at Day 29 relative to Day 1. Both doses showed a similar increase in serum antibody responses with no statistical difference between the medium and high dose arms. Results from this Phase 2 dose-ranging study also demonstrated that the bivalent norovirus vaccine candidate was well tolerated, with a favorable safety profile that included no vaccine-related serious adverse events and no dose limiting toxicity. Collectively, the data from these completed trials have shown immune responses from Vaxart's oral norovirus vaccine constructs to be strong, long-lasting, and comparable to natural infection. Additional timepoint measures and mucosal data from this study are expected in the second half of 2023. The data support the continued development of Vaxart's oral norovirus vaccine candidate in adult populations. These data will inform dosage amounts for a bivalent norovirus Phase 2b study, the next step in progressing the vaccine candidate. The Phase 2b study is expected to add safety data that, if successful, will then enable Vaxart to schedule an End-of-Phase 2 meeting with the FDA, potentially in 2024.

08:13 EDT GTCR to acquire majority stake in Worldpay from FIS - GTCR announced that it has signed a definitive agreement to acquire a majority stake in Worldpay from FIS. GTCR will acquire 55% of Worldpay, and FIS will retain the remaining 45%, in a transaction that values the business at $18.5B. As part of the agreement, GTCR has committed an additional equity capital investment in Worldpay of up to $1.25B to pursue inorganic growth opportunities. Worldpay and FIS will continue to work together closely in partnership on a commercial basis to best serve customers and deliver innovative solutions into the marketplace. Charles Drucker, the former Executive Chairman and Chief Executive Officer of Worldpay, will become CEO of the standalone Worldpay business upon close. "We are thrilled to partner with Worldpay and its talented team to drive forward this market leading business," said Collin Roche, GTCR Co-CEO and Managing Director. "Worldpay has established itself as a leader in the payments sector, and we see strong opportunity to enhance its existing physical, e-commerce and omni-channel presence through additional investment, allowing the business to capitalize on digital payment trends. We look forward to leveraging the strength of the entire organization to build an even better business, positioning Worldpay for sustainable, long-term growth."

08:12 EDT Alignment Healthcare appoints Melinda Kimbro as Chief People Officer - Alignment Health appointed Melinda Kimbro as its new chief people officer. Kimbro joined on June 30 to lead the company's human resources function. Kimbro spent over two decades at Viasat, where she helped grow the company from 500 to 7,000 employees across 20 countries. At Viasat, Kimbro served in various HR, employee relations and developmental roles, including head of HR, senior vice president of people and culture and chief people officer. She previously held positions in corporate learning and organizational development for Nicholas-Applegate Capital Management, Qualcomm Personal Electronics and Sony Electronics.

08:11 EDT Quest Diagnostics, Proov collaborate on home fertility test - Available through a collaboration with the consumer-initiated testing business of Quest Diagnostics and Proov, maker of at-home fertility and hormone tests, the Proov Confirm PdG test is the first and only FDA-cleared PdG home test kit to confirm successful ovulation. The test is the first women's health test from a third-party manufacturer available through questhealth.com. "I created Proov after my own battle with infertility because I wanted other women to have more information and options than what I had at the time," said Proov founder and CEO, Amy Beckley, PhD. "We are thrilled to collaborate with Quest to broaden access to Proov Confirm so even more women can access insights to help them realize their dream of raising a family."

08:11 EDT Altitude Acquisition extends deadline to complete business combination - Altitude Acquisition announced that its board of directors, upon request by Altitude's sponsor, Altitude Acquisition Holdco has extended the date by which Altitude must consummate an initial business combination for an additional month, from July 11, 2023 to August 11, 2023. Altitude's Amended and Restated Certificate of Incorporation, as amended, gives the Board the right to extend the Deadline Date, without further stockholder vote, up to eight times for an additional one month each time, from April 11, 2023 to up to December 11, 2023. On June 30, 2023, pursuant to the Charter and upon request from the Sponsor, the Board determined to implement a fourth Extension. As previously announced, on April 23, 2023, Altitude entered into a business combination agreement with Picard Medical and the other parties thereto, which provides for a business combination between Altitude and Picard. The purpose of this monthly Extension is to provide Altitude with additional time to consummate the proposed business combination with Picard.

08:09 EDT Thermo Fisher acquires CorEvitas from Audax for $912.5M in accretive deal - Thermo Fisher Scientific announced it has entered into a definitive agreement to acquire CorEvitas from Audax Audax for $912.5M in cash. CorEvitas manages 12 registries, including nine autoimmune and inflammatory syndicated registries. Its multi-therapeutic data intelligence platform builds and scales multiple clinical registries across specific therapeutic areas to gather structured patient clinical data spanning more than 400 investigator sites and over 100,000 patients followed longitudinally. CorEvitas has been a partner to pharma and biotech customers for more than 20 years. With approximately 300 employees, operational momentum and strong leadership, CorEvitas is well positioned to grow its revenue organically in the low double digits, with expected revenue of $110M in 2023. Raymond H. Hill, chairman and chief executive officer of CorEvitas, said, "This is an exciting next step for CorEvitas. Thermo Fisher shares our science-led and mission-driven culture and commitment to driving innovation and improving patient outcomes. I am confident that becoming part of a global leader with deep life science expertise, commercial reach, international presence, and proven operational excellence will provide significant opportunities for both our customers and our colleagues. I look forward to working with the entire Thermo Fisher team as we enter this next phase of growth." The transaction, which is expected to be completed by the end of 2023, is subject to customary closing conditions, including regulatory approvals. Upon completion, CorEvitas will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment. The transaction is expected to be immediately accretive to adjusted earnings per share by $0.03 in 2024.

08:08 EDT Asset Entities enters agreement with NFL star Michael Irvin - Asset Entities has entered into an agreement with Michael Irvin, former NFL Superstar, Hall of Fame Wide Receiver, three time Super Bowl Champion, and Emmy Award winning Sports Analyst as a consultant in the area of Sports and Entertainment and to contribute to the expansion of AE.360.DDM and its suite of services, including Asset Entities' social media marketing and other areas.

08:08 EDT electroCore's vagus nerve stimulation selected for NFL-funded concussion study - electroCore's gammaCore non-invasive vagus nerve stimulation - nVNS - has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and performance. The NFL and NFLPA are jointly awarding two research grants to independent medical researchers at the American Society of Pain and Neuroscience and Emory University. The grants will fund investigations into first-of-their-kind, alternative pain management methods that could benefit NFL players, and society at large. The randomized study will compare nVNS and cannabidiol in contact sport athletes experiencing Post-Traumatic Headache to current standard of care treatment. The pilot data gathered in this study will guide future investigations into treatment of patients with post-traumatic headache.

08:06 EDT Decibel Cannabis announces results of AGM of shareholders - Decibel Cannabis Company announces the results of its annual general meeting, AGM, of shareholders held on July 5, 2023. Results of the Meeting: Shareholders approved all matters submitted by the Company for consideration at the Meeting. At the Meeting, Shareholders: fixed the number of directors of the Company to be elected at the Meeting at five directors; elected each of Shawn Dym, Manjit Minhas, Nadia Vattovaz, Jakob Ripshtein and Paul Wilson to serve as directors of the Company; and appointed KPMG Chartered Professional Accountants, as the Company's auditors.

08:05 EDT authID announces new customer contracts - authID has secured new customer contracts with an estimated aggregate Booked Annual Recurring Revenue or BARR of approximately $239,000 during the quarter ended June 30, 2023. authID's new customers include a Fortune 500 company with over 100,000 employees, working with authID to secure workforce access to shared corporate devices and applications; a U.S. financial institution using our services to streamline customer onboarding and weed out imposters; and an international recruitment platform who need our services to verify identity of new hires and automate document collection, in order to deliver trusted candidates to their corporate customers.

08:04 EDT Aquestive Therapeutics presenting positive data of Anaphylm sublingual film - Aquestive Therapeutics announced that two posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm epinephrine sublingual film will be presented at the Global Food Allergy Prevention Summit held July 7-9 in Chicago. Anaphylaxis is a serious systemic hypersensitivity reaction with that is rapid in onset and potentially fatal.

08:04 EDT HireRight acquires majority share of Digital Trusted Identity Services - HireRight announced the acquisition of a majority share of Digital Trusted Identity Services, an FBI-approved channeler specializing in collecting and processing biometric and biographical data. This investment expands HireRight's commitment to biometric-based screening, including fingerprinting, as a critical component for customers in regulated industries - such as healthcare, financial services, transportation, and aviation - as well as non-regulated industries. The remaining minority share of DTIS is retained by the American Association of Airport Executives Inc., the world's largest professional organization representing individuals who work at public-use commercial and general aviation airports.

08:03 EDT LanzaTech appoints Zara Summers as CSO, Michael Kopke as CIO - LanzaTech Global announced the promotion of Dr. Zara Summers to Chief Science Officer and Dr. Michael Kopke to Chief Innovation Officer. In her new role, Dr. Summers will oversee the entirety of LanzaTech's Science division - which encompasses Synthetic Biology, Fermentation, AI, and Computational Biology - unifying and streamlining the Company's R&D work for commercial success. She will have accountability for the Company's technology pipeline and technical portfolio. Prior to the promotion, Dr. Summers served as LanzaTech's VP of Science. Dr. Kopke will oversee the process of innovation within the Company, including identifying next technology breakthroughs, developing and incubating technology and business opportunities for LanzaTech, and increasing organizational resilience and flexibility through its technology investments. He will continue to play a leading role in establishing and coordinating technology partnerships and innovation networks and will lead a Distinguished Technical Council at LanzaTech, that will lead on cutting edge developments that can support the Company's commercial pipeline. Prior to the promotion, Dr. Kopke most recently served as LanzaTech's VP of Synthetic Biology.

08:03 EDT Akari Therapeutics receives positive opinion from EMA on nomacopan designation - Akari Therapeutics announced that the European Medicines Agency - EMA - has issued a positive opinion on the company's application for orphan drug designation for nomacopan as a treatment in hematopoietic stem cell transplantation. The application included nomacopan clinical data from the treatment of patients with pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, or HSCT-TMA. Akari is currently conducting a registrational Phase 3 clinical trial of nomacopan in pediatric HSCT-TMA. Typically, the European Commission grants orphan drug designation 30 days after a positive opinion is issued. The EMA designates orphan drug status for medicines treating rare, life-threatening, or chronically debilitating diseases that meet certain criteria. If the designation is granted, Akari will receive scientific advice tailored for orphan drugs and, if a regulatory filing is approved, Akari also would receive extended market exclusivity.

08:01 EDT Aslan says Eblasakimab met primary endpoint in Phase 2b dose-ranging study - ASLAN Pharmaceuticals announced positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis, the TREK-AD study. Eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at week 16 versus placebo with statistical significance in three dosing arms: 600mg dosed once every 4 weeks, which was numerically the best performing arm, 400mg dosed once every 2 weeks and 300mg dosed once every 2 weeks. Eblasakimab is a novel monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. Eblasakimab's unique mechanism of action has been observed to enable specific blockade of the Type 2 receptor, preventing signaling through both interleukin 4 and interleukin 13 - the key drivers of inflammation in AD, while sparing the Type 1 receptor. In the TREK-AD Phase 2b study, 289 patients were randomized and treated in the intent-to-treat population across five dosing arms in a 1:1:1:1:1 ratio to receive one of four doses of eblasakimab or placebo for 16 weeks. Key efficacy endpoints, including EASI-75 and a validated Investigator Global Assessment of Atopic Dermatitis score of 0/1, the relevant endpoints for regulatory approval in Europe and the US respectively, are shown below: Key efficacy endpoints: Patients treated with eblasakimab 600mg Q4W, 400mg Q2W and 300mg Q2W saw a rapid onset of action in the first few weeks of treatment, with a statistically significant improvement in EASI score by week 4. Clinically meaningful improvements were achieved in other key efficacy measures compared to placebo after 16 weeks of treatment, including: Eblasakimab 600mg Q4W: 62.7% of eblasakimab treated patients achieved a reduction of at least 75% from baseline, compared to 30.7% on placebo; 34.1% of eblasakimab treated patients achieved a reduction of at least 90% from baseline, compared to 10.1% on placebo; 31.2% of eblasakimab treated patients achieved vIGA-AD score of 0 or 1, compared to 15.1% with placebo; 73.0% least squares mean reduction in EASI score from baseline, compared to 51.1% on placebo. Eblasakimab 400mg Q2W: 54.5% of eblasakimab treated patients achieved EASI-75, compared to 30.7% on placebo; 32.6% of eblasakimab treated patients achieved EASI-90, compared to 10.1% on placebo; 32.6% of eblasakimab treated patients achieved vIGA-AD score of 0 or 1, compared to 15.1% with placebo; 65.8% LS mean reduction in EASI score from baseline, compared to 51.1% on placebo; Eblasakimab 300mg Q2W; 60.7% of eblasakimab treated patients achieved EASI-75, compared to 30.7% on placebo; 37.7% of eblasakimab treated patients achieved EASI-90, compared to 10.1% on placebo; 33.1% of eblasakimab treated patients achieved vIGA-AD score of 0 or 1, compared to 15.1% with placebo; 69.8% LS mean reduction in EASI score from baseline, compared to 51.1% on placebo; Eblasakimab 400mg Q4W: The eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance. 51.9% of eblasakimab treated patients achieved EASI-75, compared to 30.7% on placebo; 24.3% of eblasakimab treated patients achieved EASI-90, compared to 10.1% on placebo; 15.0% of eblasakimab treated patients achieved vIGA-AD score of 0 or 1, compared to 15.1% with placebo. 61.9% LS mean reduction in EASI score from baseline, compared to 51.1% on placebo. Overall, discontinuation rates were comparable between the active treatment arms and higher in the placebo arm. No new safety signals were seen and the frequency of adverse events was comparable between active treatment and placebo arms. The most frequently observed AEs across all active treatment arms were nasopharyngitis, atopic dermatitis, headache and upper respiratory tract infection. Rates of conjunctivitis, injection site reactions and herpes infections were low. Further data from the Phase 2b study, including patient reported outcomes and biomarker data, is expected to be available in Q4 2023 and submitted for presentation at a future scientific congress. ASLAN plans to meet with the US Food and Drug Administration for an end-of-Phase 2 meeting and expects to initiate a Phase 3 clinical development program for eblasakimab in 2024. The Company is also conducting the TREK-DX study of eblasakimab in dupilumab-experienced patients and expects to announce topline data from that study in 1Q 2024.

07:55 EDT Strata Skin Sciences secures additional $12M financing with MidCap Financial - STRATA Skin Sciences has completed the refinancing of its existing debt agreement with a new facility from MidCap Financial. The new debt facility consists of a refinancing of the existing $8.0 million term loan and an additional $7.0 million tranche funded at closing. The Company also has the option to receive an additional $5 million tranche in 2024. The facility matures on June 1, 2028, and shall be payable monthly in arrears at an annual rate of Adjusted Term Secured Overnight Financing Rate plus 7.50%, subject to a SOFR floor of 3.50%. The term provides for interest only-payments until June 1, 2026, and straight-line amortization for the remaining term. "Adjusted Term SOFR '' means the per annum rate equal to the sum of 30-day forward-looking secured overnight Term SOFR, as published by CME Group Benchmark Administration Limited from time to time, plus 0.10% reset monthly. The Company also amended and restated the existing warrant previously issued so that it has an exercise price of $0.88 per share to purchase 800,000 shares of the Company's common stock to MidCap. The Company agreed to register the shares underlying this warrant for resale.

07:46 EDT Draganfly to expand production capacity with Saskatchewan facility - Draganfly announced it is expanding its manufacturing capacity to meet demand with a new facility in Saskatoon, Saskatchewan. This new facility in Saskatoon is designed to enable Draganfly to meet the market potential for its products and solutions. It will enable the expanded manufacturing and production of UAV systems and components, including those designed for the Draganfly Heavy Lift and Commander 3 XL drones. The facility enhances core manufacturing, assembly, integration, quality control processes and incorporates efficient design, testing, and inventory management systems that will result in increased capacity and new product production capabilities.

07:36 EDT Tradeweb Markets reports June ADV up 10.8% YoY to $1.38T - Tradeweb Markets reported total trading volume for June 2023 of $29.3T. Average daily volume, ADV, for the month was $1.38T , an increase of 10.8% year-over-year ,YoY. For the second quarter of 2023, total trading volume was $81T and ADV was $1.30T, an increase of 10.2% YoY, with preliminary average variable fees per million dollars of volume traded of $2.60.

07:34 EDT TerrAscend announces symbol change on OTC Markets - TerrAscend announced that its common shares, previously trading on the OTC Market under the ticker symbol "TRSSF", are to commence trading on the OTC Market under the ticker symbol "TSNDF" effective today, July 6, 2023. The Common Shares recently began trading under the ticker symbol "TSND" on the Toronto Stock Exchange. Moving to a new stock ticker symbol on the OTC Markets aligns with the Company's recent TSX listing. No action is required by shareholders with respect to either ticker symbol change.

07:32 EDT iSpecimen adds thirteen new biospecimen suppliers - iSpecimen has added thirteen new biospecimen suppliers to iSpecimen's proprietary Marketplace throughout the first half of 2023. The addition of these new sample providers increases the breadth and depth of biospecimen offerings for researchers, including varying sample types and formats that are both banked and prospectively collected. Additional specimen capabilities include those for environmental and food-based allergies, genitourinary disorders, pediatric conditions, pregnancy including normal, high risk, and fetal abnormalities, pulmonary and respiratory tract disorders, skin and connective tissue disorders, and much more, to be integrated into the platform. One of the new suppliers exclusively sources biospecimens from African patient pools to help improve health outcomes and advance translational and genomics research for diseases that are prevalent in African communities.

07:20 EDT White Gold begins diamond drilling at Betty Ford target, Yukon - White Gold (WHGOF) has commenced exploration diamond drilling at the Betty Ford target on the Betty property located in the White Gold District, west-central Yukon, Canada approximately 65 km southeast of the company's flagship White Gold Project which comprises 16 million tons averaging 2.23 g/t Au for 1,152,900 ounces of gold in the Indicated Resource category and 19 million tons averaging 1.54 g/t Au for 942,400 ounces of gold in the Inferred Resource category which remains open for expansion. Planned drilling at Betty Ford in 2023 will continue to evaluate the zone of near-surface high-grade gold mineralization, which has previously returned intersections of 3.46 g/t Au over 50.00 m and 1.17 g/t Au over 48.0 m during maiden drilling in 2021, and 8.94 g/t Au over 18.29 m and 1.50 g/t Au over 55.20 m in follow up drilling in 2022. The focus of the 2023 drill program is to test for a mineralized buried porphyry at depth and possible feeder contact/structure for the near-surface gold mineralization. This drill program forms part of the company's 2023 exploration program on its 350,000 hectare land package in the White Gold District, Yukon, supported by partners Agnico Eagle Mines (AEM) and Kinross Gold (KGC). Drilling at Betty Ford has encountered zones of near-surface gold mineralization which has been traced for approximately 175 m along strike. Previous drilling highlights include 3.46 g/t Au over 50.0 m, 8.94 g/t Au over 18.29 m, 1.50 g/t Au over 55.15 m and 1.17 g/t Au over 48.00 m. Four holes totalling 1,200 m are planned to further evaluate the zone of gold mineralization and also test for the presence of a mineralized buried porphyry at depth, as well as a possible feeder contact/structure for the near-surface gold mineralization.

07:16 EDT Compass Pathways: AMA releases language of CPT code for psychedelic therapeutics - COMPASS Pathways announced that the American Medical Association has released the language of its new Current Procedural Terminology III code for Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy. The code will go into effect and will be published in the CPT manual on January 1, 2024. The approval of the new category CPT III code, announced in May following an application by COMPASS and MAPS Public Benefit Corporation, was supported by the American Psychiatric Association, American Psychological Association and the National Association of Social Workers. Once effective, the new code will provide a mechanism to track and report the delivery of psychedelic treatments and will cover, subject to FDA approval, COMPASS's COMP360 psilocybin treatment, which is currently in late-stage development for treatment-resistant depression, and MAPS' MDMA-AT for post-traumatic stress disorder. The new code, reported in increments of one hour, will cover multiple psychedelic compounds with psychological support models, if approved, as well as variable staffing structures and numbers and credentials of qualified healthcare professionals. It will also offer a sub-code for the involvement of non-QHP clinical staff. The use of this category III tracking code will be key to developing optimal permanent and valued category I codes for psychedelic therapies as close as possible to their potential FDA approval.

07:13 EDT Tonix Pharmaceuticals comments on Long COVID definition conferences - Tonix Pharmaceuticals commented on two recent meetings sponsored by the National Academies of Sciences, Engineering, and Medicine in Washington, D.C. relating to the definition of Long COVID and to features of Long COVID that overlap with previously recognized infection-associated chronic conditions. Tonix Pharmaceuticals recognizes the potential benefits of defining subgroups of Long COVID patients based on their symptoms and recognizes the subgroup of Long COVID patients with symptoms that overlap with fibromyalgia. Tonix's experience advancing TNX-102 SL as a treatment for fibromyalgia is the company's motivation for undertaking the development of TNX-102 SL for the management of Fibromyalgia-type Long COVID. In April, the company completed enrollment of 63 participants in a Phase 2 proof-of-concept study of TNX-102 SL for fibromyalgia-type Long COVID. Topline results from the trial are expected in Q3. In addition, the company presented its analysis of a Fibromyalgia-type Long COVID subgroup that provided real-world evidence that the majority of Long COVID patients present with a constellation of symptoms that overlap with fibromyalgia and CFS/ME. Fibromyalgia-type Long COVID, like fibromyalgia and CFS/ME, appears to be both a subgroup of Long COVID and one of several chronic overlapping pain conditions that have in common the neurological process called central and peripheral sensitization, which is increasingly known by the term nociplastic pain.

07:12 EDT SCSU, Veeva Systems partner to deliver real-world experience to students - St. Cloud State University, SCSU, and Veeva Systems announced a partnership to enable medtech clinical research students with hands-on technology training. SCSU will integrate Veeva Vault eTMF into its graduate curriculum for the Applied Clinical Research Program located in Plymouth, MN starting in the Fall 2023 semester.

07:11 EDT Verano Holdings opens MUV Fort Pierce dispensary location - Verano Holdings announced the opening of MUV Fort Piece on Friday, July 7, the Company's 70th Florida dispensary and 131st location nationwide. MUV Fort Pierce is located at 1006 South U.S. Highway 1, and will be open Monday through Saturday from 9 a.m. to 7 p.m. and Sunday from 11 a.m. to 5 p.m., local time.

07:10 EDT Plymouth Industrial REIT announces senior management promotions - The Company recently promoted three employees to its senior management team. Benjamin Coues serves as Senior Vice President, Head of Acquisitions. Coues joined Plymouth in 2019 after 14 years at High Street Logistics Properties and has direct responsibility for all acquisition activity. Daniel Heffernan serves as Senior Vice President, Asset Management. Mr. Heffernan joined Plymouth in 2014 and has direct responsibility for over 10 million square feet of the Company's industrial properties and provides strategic leadership functions across the entire portfolio. Scott Robinson serves as Senior Vice President, Corporate Development. Mr. Robinson joined Plymouth in 2022 and is responsible for a range of corporate initiatives including participating in investment strategy, joint venture formation, capital raising activities and strategic transactions.

07:09 EDT Plymouth reports Q2 leases commencing totaling 2.1M square feet - Leases commencing during the second quarter ended June 30, 2023 totaled an aggregate of 2,103,095 square feet, all of which are associated with terms of at least six months. The Company will experience a 19.3% increase in rental rates on a cash basis from these leases. These leases included 1,440,165 square feet of renewal leases and 662,930 square feet of new leases. Consistent with the Company's full year 2023 forecast, occupancy was 98.0% and reflects budgeted roll-over that has been largely addressed as well as recent new developments now in service. Executed leases scheduled to commence during 2023, which includes the second quarter activity, total an aggregate of 4,719,317 square feet, all of which are associated with terms of at six months. The Company will experience a 19.9% increase in rental rates on a cash basis from these leases. These leases included 3,340,955 square feet of renewal leases and 1,078,362 square feet of new leases of which 93,979 square feet was vacant at the start of 2023, leaving a net 879,028 square feet, or 16% of 2023 expirations, to be addressed. The Company has already leased 1,623,791 square feet of leases that will commence during 2024 with a 14.5% increase in rental rates on a cash basis. Plymouth has three projects totaling 260,322 square feet remaining in the current phase of its development program. In Jacksonville, Florida, two industrial buildings totaling 80,322 square feet of industrial buildings are expected to be completed in the third and fourth quarters of 2023. These buildings are fully leased. In Atlanta, a 180,000-square-foot industrial building is estimated to be completed in the third quarter of 2023. This building remains under active lease up.

07:08 EDT Simplilearn announces collaboration with Google Cloud - Simplilearn has teamed up with Google Cloud Learning to be able to reach over 5 million learners on the Simplilearn platform with the latest digital skills. This collaboration is designed to provide an upskilling experience to the learners with measurable outcomes, leveraging the best-in-class Google Cloud labs and content offerings.

07:07 EDT Lumina Gold hires Ron Halas as Chief Operating Officer - Lumina Gold (LMGDF) announces that it has hired Ron Halas, P.Eng. as Chief Operating Officer. Halas has over 30 years of diverse experience including open pit and underground mining in both base and precious metals. He has worked with major mining companies including Kinross (KGC), PT Freeport Indonesia, Placer Dome, and Cominco.

07:05 EDT Hudbay Minerals and Marubeni sign MOU for Flin Flon exploration partnership - Hudbay Minerals signed a memorandum of understanding - MOU- with Marubeni that establishes the framework for a multi-year exploration partnership focused on the discovery of new deposits within trucking distance of Hudbay's existing processing facilities in Flin Flon, Manitoba. In connection with the MOU, Hudbay and Marubeni have agreed to negotiate the terms of a definitive agreement to govern the relationship between the parties and the Flin Flon properties that would form the subject of the exploration partnership. It is currently contemplated that Marubeni would be required to fund approximately $10-15M of exploration expenditures on the Project Properties and that Hudbay will act as operator and carry out the exploration activities. The MOU also provides a framework for a future joint venture between the parties if the exploration efforts are successful in discovering new deposits in the Flin Flon region. Marubeni would have the option to acquire a substantial minority equity interest in the projects, allowing the parties to jointly pursue the development of the projects. The final structure of a joint venture between the parties would be determined by the terms of a joint venture agreement.

07:04 EDT Kazia Therapeutics receives FTD by U.S. FDA for paxalisib - Kazia Therapeutics announces that its lead program, paxalisib, has been awarded Fast Track Designation, FTD, by the United States Food and Drug Administration, FDA, for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. The FDA's decision to grant FTD was based on promising clinical data from an interim analysis of an ongoing Phase 1 clinical trial in which patients with brain metastases from a primary tumour are receiving paxalisib in combination with radiotherapy. All nine evaluable patients in the trial responded to the combination of paxalisib with radiotherapy. Published benchmarks suggest a typical response rate for radiotherapy alone to be around 20-40%. Key Points: FTD is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions. FTD provides Kazia with enhanced access to FDA, including opportunities for face-to-face meetings and written consultation throughout the remaining development of paxalisib. Drugs granted FTD may also be eligible for Accelerated Approval and Priority Review, which may result in faster product approval. Paxalisib was previously granted FTD for glioblastoma in August 2020, giving paxalisib now two largely independent opportunities to access the benefits of this designation

07:03 EDT Bitfarms raises Q3 hashrate target to 6.3 EH/s with added Baie-Comeau facility - Bitfarms closed the acquisition of its newest farm in Baie-Comeau, Quebec and immediately started production at the site. As a result, Bitfarms increased its target hashrate to 6.3 EH/s by the end of Q3. Bitfarms acquired an evergreen contract with the local utility in Baie-Comeau for 22 MW of hydro power, which included a 10-year lease in an industrialized area with the option to purchase at a fixed price throughout the lease term. Total consideration was $1.9M, with $750K, or 40% paid in cash, and 820,837 Bitfarms' common shares, or 60%, issued at a price of $1.38/share.

07:02 EDT Wallbox sells over 1,000 Supernova DC fast chargers - Wallbox announced that it has reached the milestone of selling more than 1,000 of its Supernova DC fast chargers.

07:02 EDT First American appoints Jody Mulkey as chief technology officer - First American announced the appointment of Jody Mulkey as chief technology officer. In this new position, Mulkey will oversee First American's corporate product development team. Under Mulkey's leadership, the corporate product development team will be responsible for building and enhancing enterprise products that serve customers across multiple First American divisions. Prior to joining First American, Mulkey served as chief technology officer at GoodRx.

06:59 EDT FIS to create two independent companies, sell majority stake in Worldpay - FIS announced an acceleration of its previously announced separation plan to create two highly focused global companies with greater strategic flexibility. FIS has signed a definitive agreement to sell a majority stake in its Worldpay Merchant Solutions business to private equity funds managed by GTCR in a transaction valuing Worldpay at $18.5 billion, including $1 billion of consideration contingent on the returns realized by GTCR exceeding certain thresholds. The transaction maximizes shareholder value by immediately securing proceeds based on a $17.5 billion valuation, with opportunity for further upside. This attractive upfront valuation equates to a 9.8-times multiple on expected fiscal 2023 adjusted EBITDA, including estimated dis-synergies and previously unallocated corporate and other costs, which represents a material premium to FIS' recent valuation of approximately 8-times, and is aligned with leading, scaled payments players. FIS will receive upfront, net proceeds of approximately $11.7 billion while retaining a non-controlling 45% ownership interest in a new standalone joint venture. The transaction was unanimously approved by FIS' Board of Directors. The agreement will enable greater management focus and operational simplification for both FIS and Worldpay. In addition, the upfront cash proceeds will create immediate capital allocation flexibility. FIS will use proceeds from the sale to pay down debt and return additional capital to shareholders through its existing share repurchase authorization, as well as for general corporate purposes, while maintaining a strong investment grade credit rating. As part of the agreement, GTCR has committed an additional equity capital investment in Worldpay of up to $1.25 billion to pursue inorganic growth opportunities. Worldpay, one of the largest global merchant acquirers by transactions with $2 trillion in payments volume in 2022, will remain a leader of commerce solutions to merchants of all sizes. As previously announced, Charles Drucker will become CEO of Worldpay upon close of the transaction. FIS and Worldpay will enter into commercial agreements, preserving a key value proposition for clients of both businesses and minimizing potential dis-synergies. These agreements will allow Worldpay continued access to FIS products to resell to its clients, as well as access to FIS' financial institution clients as it continues to scale its bank channel. Similarly, FIS will retain access to Worldpay's marquee portfolio of commercial clients to resell its embedded finance offerings. The transaction values Worldpay at $18.5 billion, inclusive of $1 billion in additional consideration that is contingent on the returns realized by GTCR exceeding certain thresholds. The upfront valuation of $17.5 billion equates to a 9.8-times multiple on expected fiscal 2023 adjusted EBITDA, including estimated dis-synergies and previously unallocated corporate and other costs. Including the $1 billion of contingent consideration, the multiple on the transaction would increase to approximately 10.4-times. FIS will receive upfront, net proceeds of approximately $11.7 billion at close. On a pro-forma basis for the transaction, FIS expects leverage to be approximately 2.5-times, based on 2023 Adjusted EBITDA upon close. The transaction is expected to close by Q1 2024, subject to regulatory approvals and other customary closing conditions. Following the closing of this transaction, FIS' ownership interest in Worldpay will be reported as income from minority interest.

06:54 EDT Nuscale Power appoints Carl Fisher as COO - NuScale Power announced that Carl Fisher will join the company as COO beginning July 24, 2023. As COO, Fisher will lead the operations, engineering, project management, quality assurance, information technology, and regulatory affairs functions and report to John Hopkins, NuScale's President and CEO. Most recently, Fisher was Vice President of Instrumentation & Control in North America. Karin Feldman, who has served in the role of interim COO since January 6, 2023, will return to her previous position as Vice President, Program Management Office.

06:52 EDT Hut 8 Mining imines 120 Bitcoin in June - Hut 8 Mining mined 120 Bitcoin in June. Overall, 120 Bitcoin were generated, resulting in an average production rate of approximately 4.0 Bitcoin per day. "June was very productive, with key developments across our mining and high performance computing operations businesses, and progress on obtaining key regulatory approvals related to the merger with USBTC," said CEO Jaime Leverton. "We are committed to keeping that momentum going as we work diligently at closing the transaction with USBTC."

06:48 EDT Kolibri Global Energy announces three more wells in Tishomingo field - Kolibri Global Energy announced three more wells in its Tishomingo field in Oklahoma, which have been adding over 1,500 barrels of oil equivalent per day to the Company's production. The Barnes 8-1H, 8-2H, and 8-3H wells were drilled and completed under budget and are still cleaning up after the fracture stimulations. The two Caney formation wells, the Barnes 8-1H and 8-2H, have produced at a 12-day average rate of 465 BOEPD and 565 BOEPD, respectively. For the last five days, the Barnes 8-1H has averaged 500 BOEPD, and the Barnes 8-2H has averaged 590 BOEPD. These wells were the first down-spacing wells in the field and were drilled at a 6 well per section spacing pattern with the Barnes 8-1H in the upper Caney, and the Barnes 8-2H in the lower Caney. The Barnes 8-3H well, which is in the T-zone formation and is located under and between the Barnes 8-1H and 8-2H wells, has an 11-day average rate of 445 BOEPD and has averaged 490 BOEPD for the last 5 days, with the last 2 days at 570 BOEPD. Production optimization is currently in progress on all three of the wells.

06:39 EDT CloudMD shares research report on results of MindBeacon program - CloudMD Software & Services released the findings of a research report on the health outcomes delivered by CloudMD Therapist-Assisted Internet-Delivered Cognitive Behavioural Therapy program which was offered to the public of Ontario as part of the government's pandemic response. This program is digitally delivered to help treat prevalent mental health challenges, including mood and anxiety conditions. By eliminating barriers to care - including time to treatment, accessibility, and stigma - CloudMD's TAiCBT program, MindBeacon, met the needs of some 65,000 Ontarians during the COVID-19 pandemic, thanks to the support from the Ontario government. This initiative provided innovative made-in-Canada virtual services that served as an effective and economical model for the rest of the country. Key highlights from the report include: Faster time to treatment - average time to start treatment of five days compared to weeks or months. More flexible access to care - 90% of patients engaged outside traditional office hours. Cost effective - TAiCBT is 1/5th the cost of traditional treatment. Health Outcomes with effective treatment for all ages, genders, protocols and symptom severities - 60% of patients with clinically severe depression symptoms experienced reliable symptom improvement. Improvements in Health equity - 32% of patients identify as racialized persons reflecting the diverse population of Ontario. Effective for first time treatment - 51% of patients were new to therapy and accessed support for the first time.

06:36 EDT Meridian Mining completes fourth installment payment for Cabacal Project - Meridian Mining UK has completed the fourth installment payment pursuant to the terms of the Mineral Rights Purchase and Sale Agreement for the acquisition of 100% beneficial interest in the Company's flagship Cabacal Copper-Gold Project, state of Mato Grosso, Brazil. The details of the Agreement are described in the Company's news release dated August 26, 2020. Pursuant to the Agreement, the Vendors of Cabacal elected to receive 1,000,000 common shares of the Company in lieu of a cash payment of C$300,000 for the Fourth Payment. In accordance with the applicable securities regulations and policies of the Toronto Stock Exchange, the common shares issued to Vendors pursuant to the Agreement are subject to a statutory four month and a day hold period. The Company is aggressively advancing the development of the Cabacal project and the management team, led by Dr. Adrian McArthur, CEO, continues to be focused on executing its ongoing work program. The drill program at Cabacal is ongoing with three rigs operating on site, and a fourth rig expected in the coming weeks. Assay results are expected to be reported over summer and autumn, as the Company continues to target the strong upside of Cabacal, and the belt-scale upside, commencing at Santa Helena.

06:13 EDT Global Blue releases Tax Free Shopping business update for June - New data from Global Blue reveals that the overall dynamic recovery for Tax Free Shopping has accelerated across Continental Europe and Asia Pacific. Globally, issued Sales in Store like-for-like recovery has propelled to 128% in June versus 112% in April/May. This increase is due to two primary factors. Firstly, there has been a re-acceleration to Q1 2023 levels in the recovery of US and Gulf Cooperation Council shoppers in Continental Europe. Secondly, Mainland Chinese shoppers have shown an accelerated recovery, particularly in Asia Pacific, where there are fewer travel-related barriers.

06:07 EDT Comstock enters Mineral Exploration, Mining Lease agreement with Mackay - Comstock announced that its wholly-owned subsidiary Comstock Northern Exploration has entered into a Mineral Exploration and Mining Lease Agreement with Mackay Precious Metals, to lease the northernmost patented mining claims, mineral exploration rights and town lots controlled by Comstock. The Northern Targets encompass both the Gold Hill and northern Occidental Lode claim groups in the historic, world-class, Comstock Mining District located in Storey County, Nevada. The Mineral Lease has a term of 20 years and would automatically continue once mine feasibility is established and for so long as Mackay is engaged in mining operations and in full compliance with the Mineral Lease. The fees associated with the Mineral Lease included a $1.25M initiation fee that was fully paid at signing plus $1.5M per annum for the first four years, and $1M per annum thereafter, in all cases plus expense reimbursements of approximately $200,000 per year. Comstock also retains a 1.5% net smelter return royalty from all future precious metal production. The Mineral Lease contains non-competition restrictions prohibiting Mackay from staking property within two miles of any of the property owned or leased by Comstock in the District and mutual rights of first refusal with respect to the sale of certain mining assets for both parties.

06:03 EDT Patterson-UTI reports average of 126 drilling rigs in U.S. operation in June - PATTERSON-UTI ENERGY reported that for the month of June 2023, the Company had an average of 126 drilling rigs operating in the United States. For the three months ended June 30, 2023, the Company had an average of 128 drilling rigs operating in the United States.

05:40 EDT Meta's Threads surpassed 10M signups within 7 hours of launch, says Zuckerberg - Meta CEO Mark Zuckerberg said Threads surpassed 10M signups within seven hours of launch. Previously, he said that 5M people signed up four hours after Meta officially released Threads. Reference Link

05:27 EDT Astellas Pharma granted priority review for zolbetuximab BLA - Astellas Pharma announced that the FDA has accepted and granted Priority Review for the company's Biologics License Application, or BLA, for zolbetuximab, a investigational Claudin 18.2-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction, or GEJ, adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in the U.S. for these patients.

05:17 EDT UMC reports June revenue NT$19.06M, down 23.24%

05:15 EDT Wabtec wins component order for up to 504 Stadler cars - Wabtec won a contract to supply passenger information systems, or PIS, and pantographs for up to 504 Stadler cars as part of the VDV Tram-Train project. The order will enhance the passenger experience and power the new train cars for the transit consortium led jointly by six transportation companies from Germany and Austria. The company is responsible for the design, manufacturing, and delivery of the advanced PIS and pantograph systems. Over the next ten years, Wabtec will supply Stadler systems for 246 CITYLINK vehicles. The order includes an option for operators to order up to 258 more vehicles.